MedTrace Logo

A Comparison of Accelerometers for Measuring Daily Activity in Sarcoid

NCT02626897 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2015-12-10

No results posted yet for this study

Summary

This cross-over study of 12 patients with sarcoidosis will look at two different widely-used accelerometer devices. These devices are wrist worn and similar in size to a wrist-watch. They measure daily activity levels. The investigators hope to use one of these devices in the future within a randomised-controlled trial looking at using methylphenidate for the treatment of sarcoidosis-associated fatigue. In order to ensure that the investigators choose the ideal device the investigators wish to compare the GENEActiv and ActiGraph GT3X devices. Participants will be required to wear the devices for 7 days each, with 6 patients beginning with the GENEActiv device and changing to the ActiGraph device after 7 days, the remaining 6 participants starting with the Actigraph before changing to the GENEActiv. Patients will complete a short exit questionnaire about their experience with the devices and their preference. The best device will be determined by both patient preference and reliability of collecting data.

Conditions

  • Sarcoidosis

Interventions

DEVICE

GENEActiv Original Accelerometer

Wrist-worn device measuring accelerations as a measure of daily activity.

DEVICE

ActiGraph GT3X Accelerometer

Wrist-worn device measuring accelerations as a measure of daily activity.

Sponsors & Collaborators

  • University of East Anglia

    lead OTHER

Principal Investigators

  • Chris Atkins, MB/BS · University of East Anglia

  • Andrew M Wilson, MD · University of East Anglia

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2016-03-31
Completion
2016-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02626897 on ClinicalTrials.gov